Respiratory virus season has arrived, and hopefully you’re up to date on vaccinations that can help prevent infectious ...

The respiratory syncytial virus (RSV) vaccine (Abrysvo) was linked with fewer hospitalizations and emergency department (ED) ...

Study explores the clinical manifestations, risk factors, and 90-day mortality outcomes in adults hospitalized with RSV or ...

SickKids Hospital is expanding a saliva testing program across select Toronto schools, aiming to help limit the spread of ...

A multi-state study, published in The Lancet, is one of the first real world data analyses of the effectiveness of the ...

The RSV vaccine Abrysvo was highly effective against hospital and ED encounters in a large cohort of older adults with comorbidities and immunocompromising conditions.

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

Starting Oct. 28, the rest of the general public are recommended to also get vaccinated, says region's health unit ...

A large new study says the RSV vaccine is 80% effective at preventing hospitalization in older adults due to complications from the illness, and works just as well at protecting them from death or ...

Merck has reported positive Phase IIb/III trial data for clesrovimab, its investigational RSV antibody, showing a 60.4% ...

A photo collage of a "Seattleite in Fall" Halloween costume, featuring a beard man in a beanie, sunglasses, and red plaid ...